TRAX NEWS
globenewswire.com
2d ago
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
globenewswire.com
2d ago
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Calif. , May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: 2026 Jefferies Global Healthcare Conference, New York Format - Presentation and one-on-one investor meetings Date and Time - Wednesday, June 3, 2026 at 12:15pm ET / 9:15am PT Leerink Partners Therapeutics Forum, Boston Format - One-on-one investor meetings Date and Time - Tuesday, July 14, 2026 A live webcast of the presentation will be available on the investor section of the First Tracks website at https://ir.
globenewswire.com
May 14
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
seekingalpha.com
May 6
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.